Jun 28, 2019

Paul Meadows is one of the founding members of IFESS and a  veteran in the neurotech industry. He is currently the Chief Technology Officer at Imthera in the development of neurostimulation device for obstructive sleep apnea. The company was recently acquired by LivaNova. Previous Meadows was involved with neurotech development at Advanced Bionics as well as the Alfred E. Mann Foundation.

Takeaways:
1. Current technology transfer developments are influenced by peer-reviewed published research.
2. Learn from the past so we don’t repeat in the future, applies to neurotech applications.
3. We still have technology challenges in such areas as cybersecurity and battery technology as well as systemic in clinical technology adoption.

[0:00] Ladan introduces the episode and joins the conversation with Paul Meadows and Jen French.
[1:02] Paul Meadows describes his involvement and various positions with IFESS since the inception of the organization.
[1:46] Discussion of his view of the evolution of IFESS over the years.
[2:35] Meadows describes the importance of peer-reviewed publications and the need to
review past research.
[3:43] There are obstacles for technology adoption such as clinical physical therapist curriculum.
[3:58] Meadow’s outlook for exciting developments in the next 5 years in miniaturization, packaging and user-friendly interfaces. This is accompanied by identified risks such as cybersecurity.
[5:52] Identifying that there is some basic science that is limiting technology advancements such as battery technology.